894 results about "Tumor site" patented technology

The invention provides methods, systems and reagents for regulating pH-sensitive protein interaction by incorporating non-natural amino acids into the protein (e.g. an antibody, or its functional fragment, derivative, etc.). The invention also relates to specific uses in regulating pH-sensitive binding of antibodies to tumor site, by conferring enhanced tumor-specificity / selectivity. In that embodiment, the non-natural amino acids preferably have desirable side-chain pKa's, such that at below physiological pH (e.g. about pH 6.3-6.5) the non-natural amino acid confer enhanced binding to tumor antigens in acidic environments. Such non-natural amino acids can be incorporated by any suitable means, such as by utilizing a modified aminoacyl-tRNA synthetase to charge the nonstandard amino acid to a modified tRNA, which forms strict Watson-Crick base-pairing with a codon that normally forms wobble base-pairing with natural tRNAs (e.g. the degenerate codon orthogonal system.

The present invention provides drug delivery vehicles comprising polytheylyene-lipid conjugates (PEG-lipid), wherein the circulation lifetime and biodistribution of the drug delivery vehicles are regulated by the PEG-lipid. More particularly, the present invention provides liposomes, SNALP and SPLP comprising such PEG-lipid conjugates, and methods of using such compositions to selectively target a tumor site or other tissue of interest (e.g., liver, lung, spleen, etc.).

A system and process is provided for dynamically positioning or repositioning a robot in a surgical context based on workspace and task requirements, manipulator requirements, or user preferences to execute a surgical plan. The system and method accurately determines and indicates an optimal position for a robot with respect to a patient's anatomy before or during a surgical procedure. Optimal positions for a robot are intuitively indicated to a user, surgical procedures can illustratively include surgery to the knee joint, hip joint, spine, shoulder joint, elbow joint, ankle joint, jaw, a tumor site, joints of the hand or foot, and other appropriate surgical sites.

The invention provides methods, systems and reagents for regulating pH-sensitive protein interaction by incorporating non-natural amino acids into the protein (e.g. an antibody, or its functional fragment, derivative, etc.). The invention also relates to specific uses in regulating pH-sensitive binding of antibodies to tumor site, by conferring enhanced tumor-specificity / selectivity. In that embodiment, the non-natural amino acids preferably have desirable side-chain pKa's, such that at below physiological pH (e.g. about pH 6.3-6.5) the non-natural amino acid confer enhanced binding to tumor antigens in acidic environments. Such non-natural amino acids can be incorporated by any suitable means, such as by utilizing a modified aminoacyl-tRNA synthetase to charge the nonstandard amino acid to a modified tRNA, which forms strict Watson-Crick base-pairing with a codon that normally forms wobble base-pairing with natural tRNAs (e.g. the degenerate codon orthogonal system.

The present invention is directed to methods for treating cancer wherein more than one therapeutic agent is used, with each of the therapeutic agents having different tumor-killing capabilities, and wherein the therapeutic agents are delivered to the tumor sites using combined targeting and pre-targeting methods. The methods of the present invention achieve good tumor to non-tumor ratios of the therapeutic agents, and are effective for cancer therapy.

S-band, C-band or X-band microwave powered linear accelerators capable of delivering therapeutic photon and electron beams are mounted to a gantry with extensions to hold multiple accelerators and are combined with a kV CT for 3-D conformal—IMRT and IGRT to treat a patient by SSD or SAD methods and in a full circle. The invention's tertiary collimator system consists of semi-automated reusable custom field shaping with tungsten powder or melted Cerrobend blocks. The beam's intensity modulation is by means of simultaneous but independently operating multiple accelerators. This system's multiple accelerators enable to avoid interrupted subfractionated radiation therapy to each treatment fields. Hence its effective dose rate at the tumor site is high. The improved radiobiology reduces the total radiation dose to treat a tumor, reducing the incidence of developing second primary tumors is also minimized.

A system and process is provided for dynamically positioning or repositioning a robot in a surgical context based on workspace and task requirements, manipulator requirements, or user preferences to execute a surgical plan. The system and method accurately determines and indicates an optimal position for a robot with respect to a patient's anatomy before or during a surgical procedure. Optimal positions for a robot are intuitively indicated to a user, surgical procedures can illustratively include surgery to the knee joint, hip joint, spine, shoulder joint, elbow joint, ankle joint, jaw, a tumor site, joints of the hand or foot, and other appropriate surgical sites.

A medical accelerator system is provided for simultaneous radiation therapy to all treatment fields. It provides the single dose effect of radiation on cell survival. It eliminates the inter-field interrupted, subfractionated fractionated radiation therapy. Single or four beams S-band, C-band or X-band accelerators are connected to treatment heads through connecting beam lines. It is placed in a radiation shielding vault which minimizes the leakage and scattered radiation and the size and weight of the treatment head. In one version, treatment heads are arranged circularly and connected with the beam line. In another version, a pair of treatment heads is mounted to each ends of narrow gantries and multiple such treatment heads mounted gantries are assembled together. Electron beam is steered to all the treatment heads simultaneously to treat all the fields simultaneously. Radiating beam's intensity in a treatment field is modulated with combined divergent and pencil beam, selective beam's energy, dose rate and weight and not with MLC and similar devices. Since all the treatment fields are treated simultaneously the dose rate at the tumor site is the sum of each of the converging beam's dose rate at depth. It represents the biological dose rate. The dose rate at d-max for a given field is the individual machine dose rate. Its treatment options includes divergent or pencil beam modes. It enables to treat a tumor with lesser radiation toxicities to normal tissue and higher tumor cure and control.

A medical accelerator system consisting of coplanar and non-coplanar beams, on line magnetic resonance anatomic and functional imaging and cone beam computed tomographic imaging for single session image guided all field simultaneous radiation therapy and radiosurgery is provided. This system enables single session simulation, field-shaping block making, treatment planning, dose calculations and treatment of tumors. The radiation exposure time to the tumor and the normal tissue is reduced to a few seconds to less than a minute. In filed intensity modulated radiation is rendered by combined divergent and pencil beam, multiple smaller fields within a larger field, selectively varying beam's energy, dose rate and beam weight. Since all the treatment fields are treated simultaneously the dose rate at the tumor site is the sum of each of the converging beam's dose rate at depth. This super-high biological dose rate impairs the lethal and sublethal damage repair.

A computerized system collects, organizes and stores various sets of data during several phases of treatment relating to monitoring and location of a route in vivo and a visible image of that route for retrograde perfusion of a tumor with a therapeutic agent and for monitoring treatment procedures during such retrograde perfusion. The data obtained from present and past treatment procedures are stored for analysis and also made available real time to treating physicians during treatment procedures.

A computerized system collects, organizes and stores various sets of data during several phases of treatment relating to monitoring and location of a route in vivo and a visible image of that route for retrograde perfusion of a tumor with a therapeutic agent and for monitoring treatment procedures during such retrograde perfusion. The data obtained from present and past treatment procedures are stored for analysis and also made available real time to treating physicians during treatment procedures.

The invention provides a tumor chemotherapeutic medicinal preparation and a preparation method thereof. The tumor chemotherapeutic medicinal preparation comprises a cell vesicle derived from apoptotic tumor cells and a chemotherapeutic medicine which is wrapped in the cell vesicle and serves as an active ingredient. The chemotherapeutic medicine in the medicinal preparation comprises an active ingredient for treating tumor which provides the cell vesicle. The invention also provides a preparation method for the tumor chemotherapeutic medicinal preparation. By the technical scheme provided by the invention, the chemotherapeutic medicine can be selectively released at the tumor site, so that the chemotherapeutic medicine can exert medicine effect continuously, the killing effect of the chemotherapeutic medicine on the tumor cells can be improved, and the toxic or side effect of the chemotherapeutic medicine on the normal cells can be reduced.

The invention discloses a tumor-targeted nanometer drug delivery system for cooperative chemotherapy and photodynamic therapy and a preparation method thereof. The drug delivery system is prepared from carboxymethyl chitosan, folate, a photosensitizer chlorine e6 and adriamycin, wherein the chlorine e6 and the folate are coupled to a carboxymethyl chitosan chain segment through an amido bond, and are loaded to polymer nanoparticles of the adriamycin through an ion exchange method. The nanometer material prepared by the method is high in yield, regular in shape and even in distribution. In-vivo and in-vitro experiments prove that the tumor targeting property of the nanometer preparation can be significantly improved by folate receptor mediation; enrichment on the tumor part is achieved and drug release is controlled. The photosensitizer is capable of effectively reversing the chemotherapy drug resistance and significantly inhibiting the growth of tumors after being irradiated by near-infrared light. Therefore, the related nanometer drug delivery system has good application prospect in the aspect of breast cancer treatment.

A therapy apparatus for producing thermal neutrons at a tumor site in a patient has a plurality of fast neutron sources surrounding a moderator, a fast neutron reflecting media around the fast neutron sources, a gamma-ray and neutron shielding media surrounding the fast neutron reflecting media, and a patient chamber positioned inside the moderator. The fast neutron sources are positioned around the moderator to maximize and direct the neutron flux to said tumor site.

The invention relates to a somatostatin receptor-mediated tumor targeted pharmaceutical composition which adopts a targeted somatostatin receptor functional polypeptide and polyethylene glycol for simultaneously modifying a pharmaceutical carrier, and an anti-tumor drug or / and an anti-angiogenic drug is delivered to the tumor part, thereby enhancing the tumor treatment effect.

A microbeam intraoperative, 10-50 kilovoltage radiation therapy system with multiple simultaneous microfocus X-ray sources and method for image guided, microsecond duration, 100 to 1,000 Gy microbeam radiation therapies with dose rate ranging from 1,000 to 20,000 Gy per second and RBE closer to high LET with minimal toxicity to normal tissue is provided. Dismountable coronal, sagital and transverse half-circle gantry sections are assembled on to a surgical table for mounting the microfocus X-ray sources for intraoperative radiosurgery. A stereotactic breast core biopsy system is adapted for combined breast biopsy, positron emission tomography and computerized tomography with phase-contrast imaging. Cosmetic whole breast preserving electronic brachytherapy is combined with stereotactic core biopsy. The low dose valley regions of the intersecting microbeams at the tumor site are filled with scattered and characteristic radiation from high Z-element that is bound or implanted into the tumor.

The invention discloses a dual target liposome and a preparation method and application thereof. The target liposome provided by the invention consists of liposome and modifiers on the surface of the liposome, wherein the modifiers on the surface of the liposome comprise p-aminophenyl-alpha-D-manno-pyranoside and transferrin. The invention also discloses a medicament-loaded liposome, which is obtained by wrapping daunorubicin by using the target liposome. The obtained target liposome has good capability of crossing the blood brain barrier, targets brain glioma, and can be used as a medicament carrier. The medicament-loaded liposome can target the medicament to a brain glioma site after crossing the blood brain barrier so as to greatly increase the concentration of the medicament at a tumor site and improve the effect of chemotherapy. The target liposome provides a new measure for brain glioma chemotherapy, contributes to the research of non-invasive therapy of the brain glioma, and has important theoretical meaning and clinical meaning.

The invention relates to a folate-targeted reduction sensitive drug-carrying polymer nano-micelle as well as a preparation method and application thereof. The delivery carrier is prepared by taking anamphiphilic triblock copolymer PCL-ss-PEG-ss-PCL as a material, and a chemotherapeutic drug adriamycin amycin and a photosensitizer indocyanine green are entrapped in a hydrophobic core of the micelle. Besides, phospholipid DSPE-PEG-NH2 with an active group is introduced into the preparation process, the DSPE end of the phospholipid has strong hydrophobic property and is inserted into the hydrophobic PCL core of the polymer micelle, the flexible hydrophilic PEG long chain exists on the outer surface of the micelle, FA with a targeting effect is connected to a PEG active distal end of the surface of the polymer micelle, and functions of active tumor targeting and reduction response drug release are integrated. The folate-targeted reduction sensitive drug-carrying polymer nano-micelle disclosed by the invention has the advantages of being small in particle size, high in dispersion property, high in drug loading capacity and encapsulation efficiency and excellent in photothermal conversion effect, can realize reduced trigger drug release, fluorescence imaging of tumor sites, tumor targeting drug delivery and chemotherapy-photothermal combination therapy and improve the tumor inhibition effect, and has wide application prospects in the targeted combination therapy aspect of tumors.

The invention relates to a pH / reduction dual-sensitive multifunctional nano-micelle for tumor chemotherapy and photothermal combined therapy and application of the pH / reduction dual-sensitive multifunctional nano-micelle. The pH / reduction dual-sensitive multifunctional nano-micelle is characterized in that a PCL-acetal-PEG polymer with pH sensitive characteristic, a PCL-ss-PEG-ss-PCL polymer withreduction sensitive characteristic and a phospholipid DSPE-PEG-NH2 with an active group are used as raw materials and are blended to prepare a pH / reduction intelligent responsive polymer nano-micelleas a carrier; a chemotherapeutic drug and a photosensitizer coat a hydrophobic core of the micelle; a casing is made of hydrophilic PEG and has the characteristic of long circulation and space stability; a folic acid targeting group is modified on the surface of the micelle by a covalent bond; the drug loading capacity is 4 to 10 percent, and the mass ratio of the chemotherapeutic drug to the photosensitizer is 0.5 to 2; the particle size is smaller than 200 nm. The pH / reduction dual-sensitive multifunctional nano-micelle disclosed by the invention has the advantages of good dispersity, smallparticle size, better photothermal conversion effect and high drug loading capacity and encapsulation efficiency; the effect of improving tumor suppression by tumor targeted administration, fluorescence imaging of a tumor site, pH / reduction triggered drug release and chemotherapy and photothermal combined therapy can be realized; the pH / reduction dual-sensitive multifunctional nano-micelle has a broad clinical application prospect in combined targeting therapy of tumors.

The invention discloses an application of metal fullerene monocrystal nanoparticles in preparation of a tumor vascular disrupting agent. The monocrystal nanoparticles are water-soluble metal fullerene nanoparticles with the surface charged with negative electricity, and have the particle size range of 50-250 nm; the nanomaterial can absorb and convert outside world radiation energy into heat energy, and the volume is expanded sharply when a temperature reaches a phase transition point. During treatment, a tumor-carried living organism is injected and given with the metal fullerene monocrystal nanoparticles; the metal fullerene monocrystal nanoparticles reach a tumor part through blood circulation, and are stranded at tumor pores and defective parts; under the action of the outside world radiation energy, the metal fullerene monocrystal nanoparticles accumulate heat, the temperature rises, and the volume is expanded sharply when the temperature exceeds the phase transformation critical point, so that morphological structures or functions of tumor vascular endothelial cells are changed, and tumor vessels are interdicted so as to make the tumor cells starved to death.

A method for diagnosing certain types of cancers provides a nanoparticle agent to be uptaken by cancer cells for diagnosis and treatment of certain cancers. A compound containing nanoparticles is directed toward a tumor site, and then a predetermined time period passes to allow the nanoparticles to be uptaken by the cancer cells. Imaging is then performed on the nanoparticles by an appropriate imaging device to determine the concentration of nanoparticles uptaken by the cancer cells. Finally, image data provided by the imaging device is analyzed to determine the concentration of nanoparticles and thereby determine whether a tumor is present. The nanoparticle agent can further be employed as a treatment of certain cancers. After the uptake of nanoparticles into the cells, a predetermined field applied to the nanoparticles for a sufficient period of time activates the magnetic cores of the nanoparticles to include hyperthermia-mediated destruction of the cancer cells.

The invention discloses a near-infrared fluorescent magnetic micro-emulsion nanometer particle, its preparation method and application in tumor treatment, wherein magnetic nano-particles and near-infrared luminescent quantum dot nano-particles or near-infrared luminescent organic dyestuff molecules are embedded into water-in-oil micro-emulsion, anti-cancer drugs can also be embedded into the micro-emulsion, the magnetic steering action of the magnetic nano particles will target the micro-emulsion embedded near-infrared fluorescent substances to tumor positions or secure them onto tumor positions under the excitation of near-infrared lights, the thermal effects produced by the near-infrared lights can kill tumor cells, the OH and O2 free radicals with high activity and the optical catalytic activity of the quantum dots can also have synergic actions in destroying tumor cells.

The invention designs and synthesizes a series of paclitaxel-oleic acid small-molecular prodrugs; with the application of a chemical connecting arm which is sensitive to an oxidation-deoxidation environment, the rapid release of the drugs in tumor cells is promoted. On the basis, small-molecular prodrug self-assembled nano-drug delivery systems are prepared. The small-molecular prodrug self-assembled nano-drug delivery systems have the advantages that by virtue of a one-step nano-precipitation method, nano-drug self-assembled nanoparticles are simple in preparation process and easy for industrialization; the nano-drug self-assembled nanoparticles are small and uniform in grain size (to 100nm), and the nano-drug self-assembled nanoparticles are enriched in a tumor part by virtue of an EPR (enhanced permeability and retention) effect; an ultrahigh drug-loading capacity is guaranteed, which is beneficial for reducing adverse reactions caused by auxiliary materials and biological materials; surface modification is easy to implement, and the intake of a reticuloendothelial system can be effectively avoided and the intake of the tumor cells to the nanoparticles can be improved by virtue of PEG (polyethylene glycol) and active targeting modification; and on the basis of the sensitivity of the chemical connecting arm to the oxidation-deoxidation microenvironment of the tumor cells, the specific drug release of paclitaxel in the tumor part is achieved, a curative effect is improved and toxic and side effects are reduced.

A distributor for a system for interactive interstitial photodynamic and photothermal tumor therapy and tumor diagnosis, comprises a plurality of primary radiation conductors arranged for conducting radiation to and from the tumor site, a plurality of secondary radiation conductors, two flat discs abutting against each other, wherein a first of said discs is fixed and the second of said discs is turnable relatively to the other disc, and each disc has holes arranged on a circular line. The proximal ends of the primary radiation conductors are fixed in the holes of the fixed disc and distal ends of the secondary radiation conductors are fixed in the holes of the turnable disc, whereby the primary and the secondary radiation conductors by rotation of the turnable disc are connectable to each other in different constellations.

A therapy apparatus for producing thermal neutrons at a tumor site in a patient has a plurality of fast neutron sources surrounding a moderator, a fast neutron reflecting media around the fast neutron sources, a gamma-ray and neutron shielding media surrounding the fast neutron reflecting media, and a patient chamber positioned inside the moderator. The fast neutron sources are positioned around the moderator to maximize and direct the neutron flux to said tumor site.

The invention provides microparticles or nanoparticles for treatment of tumors comprising: (i) a targeting agent to the tumor or the tumor environment; and (ii) at least one inducer that stimulates a desired immune response in the tumor environment, leading to tumor apoptosis, wherein components (i) and (ii) are non-covalently or covalently attached to the surface of said microparticles or nanoparticles. The targeting agent is an agent that recognizes and binds to an antigen, a receptor or other molecules found on the surface of tumor cells or in the tumor environment and are preferably antibodies.

The invention provides a tumor site identification device which spectroscopically detects the fluorescence of protoporphyrins present at a tumor site in a test subject, wherein the protoporphyrins are protoporphyrin IX (PpIX) and photo-protoporphyrin (PPp), and the identification device comprises a light irradiation unit that converts part of PpIX to PPp, a light splitting unit that splits the fluorescence of PpIX and the fluorescence of PPp, a spectroscopic detection unit that detects the relative fluorescence intensities of the fluorescence of PpIX and the fluorescence of PPp, and a tumor discrimination unit that discriminates between a tumor site and a non-tumor site on the basis of the relative fluorescence intensities of PpIX and PPp.

The invention provides a nanogel with hydrophilic and hydrophobic reversal, charge reversal and intracellular redox responsiveness on the basis of pH regulation. The nanogel is prepared by cross-linking of thermo-sensitive monomer with controllable radical polymerization, amphoteric ionic monomer and amido-containing pH sensitive monomer through a disulfide-bond-containing cross-linking agent. The invention further provides a nanogel drug carrier system with smart response to tumor microenvironment and its preparation method. On the condition of blood pH 7.4, the nanogel is in a hydrophilic swelling state that is favorable for avoiding being phagocytosed by the reticuloendothelial system (RES) and accordingly, the nanogel has blood long circulation capacity; on the condition of tumor tissue subacidity, the state of the nanogel is reversed into a hydrophobic shrinking state that is favorable for the nanogel to realize effective concentration, depth penetration and be absorbed effectively by tumor cells on the tumor location. Besides, in the intracellular lysosome environment, negative charge of the nanogel is reversed into positive charge, which is favorable for the nanogel to escape from the lysosome; and then the nanogel releases drugs responsively in cytoplasm high-GSH environment, thereby achieving a good tumor inhibition effect.

Provided is a novel peptide ligand (Leu-Ala-Arg-Leu-Leu-Thr) for binding to an EGFR surface pocket based on its 3D crystal structure. When conjugated to the distal end of liposome surface PEG moieties, the peptide ligand directs liposome binding and uptake by EGFR high expressing cancer cells (H1299 and SPCA1) specifically and efficiently. The targeted delivery of liposomal anticancer drug doxorubicin results in better therapeutic efficacy towards cells in vitro. In vivo, the targeted liposomes are injected via tail vein and the time course of their distribution and accumulation in xenograft tumor tissues are studied using a live animal fluorescence imaging system. The LARLLT targeted liposomes were seen to gradually concentrate at the tumor site and be preferentially retained more than 80 hours after injection.

The invention provides a hollow manganese dioxide (MnO2) composite nanomaterial, a preparation method and application thereof. The method comprises the steps that manganese dioxide is dissolved into an ethyl alcohol and basic solution mixed solution, and hydrolysis is performed to obtain silicon dioxide nano-particles; a water solution of the silicon dioxide nano-particles is mixed with a potassium permanganate solution, a reduction reaction is performed, etching is performed, and hollow MnO2 nano-particles are obtained; the surfaces of the hollow MnO2 nano-particles are modified by a Polypropylene amine hydrochloride layer, a polyacrylic acid layer and an aminated polyethylene glycol layer in sequence, and the hollow MnO2 composite nanomaterial is obtained. According to the method, a large number of MnO2 composite nano-materials with the controllable morphology and hollow structures can be obtained through one experiment, and the repeatability is good; the good water solubility and biocompatibility are achieved, drugs are efficiently loaded and released particularly at a tumor site; the MnO2 composite nanomaterial is combined with anti-PD-L1 for use, original tumors can be efficiently killed, and growth far-end tumors can be obviously restrained.